logo
welcome
Reuters

Reuters

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs

Reuters
Summary
Nutrition label

78% Informative

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence.

Analysts estimate the obesity drug market would be worth $150 billion in the next decade .

VR Score

89

Informative language

98

Neutral language

17

Article tone

formal

Language

English

Language complexity

61

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links